Ideaya Biosciences (IDYA) said Monday that initial data from an ongoing phase 1/2 trial of its investigational drug IDE397 in combination with Gilead Sciences' (GILD) Trodelvy showed "positive" results in patients with late-line methylthioadenosine phosphorylase-deletion urothelial cancer.

Of 19 patients evaluated, 33% who received the smaller dose of IDE397 and 57% of those who received the larger dose showed an overall response to the combination treatment, the company said.

"The results set the stage for further testing of the combination in non-small cell lung cancer, where we have just dosed the first patient in our clinical trial," said Darrin Beaupre, Ideaya's chief medical officer.

The drug combination showed a safety profile consistent with known adverse events of both drugs as single agents, the company said.